Amplimexon imexon: Phase II started

AmpliMed began a double-blind, U.S. Phase II trial to evaluate 1,000 mg/m 2 of IV gemcitabine with or without 875 mg/m 2 of IV Amplimexon in 124 treatment-naïve patients. Gemzar gemcitabine is market...